Neuroendocrine Tumors Clinical Trials

383 clinical trials for Neuroendocrine Tumors across international registries, including 82 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer — RECRUITING · PHASE2
• Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET) — RECRUITING · PHASE1
• The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue) — RECRUITING · PHASE2
• Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies — RECRUITING
• TARGETed Therapy Drug MONITOring in DIGestive Oncology — RECRUITING · NA
• A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors — RECRUITING · PHASE1
• Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors — RECRUITING · PHASE2
• An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors — RECRUITING · PHASE1
• Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types — RECRUITING · PHASE1
• Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment — RECRUITING
• Integrated Cancer Repository for Cancer Research — RECRUITING
• Safety, Tolerability and Preliminary Efficacy of NEUK203-13 in Refractory Neuroendocrine Tumor Patients — RECRUITING · PHASE1
• A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors — RECRUITING · PHASE1
• Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs. — RECRUITING · PHASE1
• Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department — RECRUITING · NA
• CapTemY90 for Grade 2/3 NET Liver Metastases — RECRUITING · PHASE2
• Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET — RECRUITING · PHASE2
• EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer. — RECRUITING · NA
• Study of the Value of hPG80 (Circulating Progastrin) for the Diagnosis of Neuroendocrine Tumours in Patients With an MEN1 Mutation — RECRUITING
• Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, BTC or NEN — RECRUITING · NA
• Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus. — RECRUITING · PHASE3
• 68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors — RECRUITING · PHASE2
• SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET) — RECRUITING · PHASE1
• Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma — RECRUITING · PHASE2
• Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors — RECRUITING · PHASE2
• Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer — RECRUITING · PHASE1
• Agnostic Therapy in Rare Solid Tumors — RECRUITING · PHASE2
• Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy — RECRUITING · PHASE3
• Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors — RECRUITING
• Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring — RECRUITING · PHASE2
• Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors — RECRUITING · PHASE2
• Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors — RECRUITING · PHASE1
• A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG — RECRUITING
• Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic Neuroendocrine Tumors — RECRUITING · PHASE2
• 18F-DOPA II - PET Imaging Optimization — RECRUITING · PHASE3
• A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy — RECRUITING · PHASE1
• Sapu003 in Advanced mTOR-sensitive Solid Tumors — RECRUITING · PHASE1
• F-Tryptophan PET/CT in Human Cancers — RECRUITING · PHASE1
• Influence of Tumour and Patient's Related Factors on the Response to Medical Treatments in Well Differentiated GEP-NENs — RECRUITING
• Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms — RECRUITING · PHASE4
• Lutathera and ASTX727 in Neuroendocrine Tumours — RECRUITING · PHASE1
• Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC) — RECRUITING
• SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry — RECRUITING
• A PHASE 2/3, MULTICENTER, RANDOMIZED OPEN LABEL STUDY OF ZANZALINTINIB VS EVEROLIMUS IN PARTICIPANTS WITH PREVIOUSLY TREATED, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NEUROENDOCRINE TUMOURS — RECRUITING · PHASE2
• A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit — RECRUITING · PHASE1
• A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors — RECRUITING · PHASE1
• Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies — RECRUITING · PHASE1
• Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors. — RECRUITING · PHASE3
• PHASE 1 FIRST-IN-HUMAN (FIH), DOSE ESCALATION AND DOSE EXPANSION STUDY OF RYZ401, A NOVEL RADIOPHARMACEUTICAL THERAPY LABELED WITH ACTINIUM-225 (225AC), IN SUBJECTS WITH NEUROENDOCRINE TUMORS (NETS) AND OTHER SELECTED SOLID TUMORS EXPRESSING SOMATOSTATIN RECEPTORS (SSTRS) — RECRUITING · PHASE1
• Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors — RECRUITING · NA

Refine this search